key: cord-1037296-hem50mqq authors: Ahmed, Jaafar Omer; Ahmed, Shwan Abdubakr; Hassan, Marwan Nasih; Kakamad, Fahmi H.; Salih, Rawezh Q.; Abdulla, Berwn A.; Rahim Fattah, Fattah Hama; Mohammed, Shvan H.; Ali, Razhan K.; Salih, Abdulwahid M. title: Post COVID-19 neurological complications; a meta-analysis date: 2022-03-03 journal: Ann Med Surg (Lond) DOI: 10.1016/j.amsu.2022.103440 sha: 80eb1dca692a15b4fef08d35699b3951c953aeaf doc_id: 1037296 cord_uid: hem50mqq INTRODUCTION: Despite numerous studies regarding neurological manifestations and complications of COVID-19, only a few cases of neurological consequences following complete recovery from SARS-CoV-2 infection have been described. OBJECTIVES: The current study aims to present a quantitative meta-analysis of published studies regarding the post-infectious neurological complications of COVID-19. DATA SOURCES: The Web of Science, PubMed, MEDLINE on OVID, and Google scholar were searched for English-language researches published after January 1, 2020. RESULT: The review of the literature revealed 60 cases - of which 40 (66.7%) cases were male, and 18 (30%) were female. The average age was 44.95 years. Overall, 17 (28.3%) patients had comorbid conditions. Twenty-four (40%) patients were hospitalized during an active COVID-19 infection. The average interval from the COVID-19 infection to the onset of neurological sequelae was 33.2 days. Guillain-Barre syndrome was the most commonly reported neurological condition (15, 25%). CONCLUSION: Despite recovery from acute infection, the pandemic highlights the significance of ongoing, comprehensive follow-up of all COVID-19 patients - even those initially believed to be asymptomatic. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the rapidly evolving coronavirus disease 2019 (COVID-19) pandemic [1] . SARS-CoV-2 is most commonly associated with pulmonary infection, resulting in pneumonia, but new studies have indicated that many other organ systems, including the cardiovascular, immunological, neurological, and gastrointestinal systems can be involved. [2] . Although various neurological sequelae in COVID-19 individuals have been identified, the specific relationship between the infection and neurological disorders remains unknown. In a case series in Wuhan, China, 36.4% of the Covid-19 cases experienced central nervous system (CNS) symptoms, 8 .9% peripheral nerve system (PNS) symptoms, and 10.7% reported skeletal muscle symptoms [3] . Neurological features do not always necessitate a direct infection of the PNS or CNS but can alternatively arise as a result of a severe systemic reaction to a viral illness outside the nervous system. However, reports of meningitis and encephalitis in the context of COVID-19 have been reported in recent months, suggesting that SARS-CoV-2 can directly infect the nervous system [4] . The reason for this involvement is that the SARS-COV-2 spike protein has a high affinity for binding to the angiotensin-converting enzyme 2 (ACE-2) receptor, which has recently been discovered on neurons and glial cells in several brain structures [5] . Other contributing factors include secondary hypoxia, cytokine-related damage, and retrograde transit via the olfactory nerve and bulb [6] . Studies on SARS-CoV-1 and MERS revealed that a minority of patients do not return to normal life quality after infection and may experience several neurological complications even for years after acute infection [7] . Despite numerous studies regarding neurological manifestations and complications of COVID-19, only a few cases of neurological consequences following complete recovery from SARS-CoV-2 infection have been described [8] . As a result, recognizing the neurological and musculoskeletal complications of COVID-19 would be valuable and might give more information to help understand the post-infectious complications of COVID-19. The current study aims to present a quantitative meta-analysis of published studies regarding the post-infectious neurological complications of COVID-19. The findings indicate a total of 55 cases. There were 37 (67.3%) male cases and 16 (29.1%) female cases, and the remainder was inapplicable. The average age was 48.27 years, ranging from 7 months to 81 years. Overall, 17 (30.9%) patients had comorbid conditions such as diabetes, hypertension, dyslipidemia, IHD, and acute lymphoid leukemia (ALL), whereas 27 (49.1%) cases had no prior medical history and the remainder was not addressed. During COVID-19 illnesses, 24 (43.6%) patients were hospitalized with 3 (5.5%) of them being admitted to the intensive care unit (ICU), and the other 12 cases were not reported as to whether they were admitted to the hospital or not (20%). The average interval from the infection of COVID-19 to the onset of neurological symptoms was 33.2 days, ranging from 8 days to 130 days. Guillain-Barre syndrome (GBS) was the most commonly reported neurological condition (12, 21.8%), followed by stroke (9, 16.4%) and optic neuritis (7, 12.7%). Table 1 shows the characteristics of the studies that were involved. The occurrence of each reported neurological condition was disclosed in Table 2 . Table 3 displays the characteristics of each condition (mean age, hospital, and ICU hospitalization). Guillain-Barré syndrome 12 [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] J o u r n a l P r e -p r o o f Stroke 9 [10] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [30] Parkinsonism 1 [29] Optic neuritis 7 [31] , [32] , [33] , [34] , [35] , [36] Status epilepticus 3 [37] , [38] , [ The COVID-19 outbreak has been a disaster worldwide, affecting many people's health and financial well-being all across the world [49] . Even though the majority of SARS-CoV-2 infected individuals recover completely, for a significant number of patients, surviving COVID-19 may be the beginning of many struggles on the long journey to complete recovery, as they develop long-term morbidities ranging from moderate to severe sequelae [50] . Since the development of COVID-19, neurological symptoms, syndromes, and consequences linked with this multi-organ viral infection have been recorded, and many aspects of neurological involvement are becoming more apparent [51] . COVID-19-related neurological consequences pose a danger to patients' functional capacity and life. Suspicion of these illnesses, careful management of metabolic changes, cardiovascular risk factors, and effective and safe treatment of these individuals are all ongoing challenges throughout the outbreak [52] . The published studies regarding post-infectious neurological complications of COVID-19 were Encephalitis 52. 2 3 2 0 4 1 0 0 5 0 3 2 0 Bell's palsy 30.3 2 1 0 3 0 0 1 2 0 1 2 0 Vestibulocochlear neuritis 36 0 1 0 0 1 0 0 1 0 0 1 0 Opsoclonus Myoclonus Syndrome 63 1 0 0 0 1 0 0 1 0 1 0 0 Myopathy 48.6 3 1 0 1 0 3 1 0 3 1 0 3 J o u r n a l P r e -p r o o f evaluated in the current study, which is the first meta-analysis on this subject. The result of this study showed a total of 55 cases who developed various neurological sequelae after recovering from an acute infection of SARS-CoV-2. COVID-19 has been classified into four stages: acute respiratory distress syndrome, cytokine storm, acute hypercoagulable condition, and autonomic dysfunction [51] . Increased IL-6 drives B-cell differentiation and has an anti-inflammatory effect. However, it has the potential to produce acute phase cytokine overproduction and cytokine release syndrome (cytokine storm), which is characterized by fever and multi-organ failure [53] . It has been proposed that in cured patients, SARS-CoV-2 stays latent in the central nervous system for an extended period, making it capable of reactivating and causing neurological problems [52] . The "post-covid neurological syndrome" provides a diagnostic dilemma for the clinical neurologist due to its many manifestations: central and peripheral nervous system, musculoskeletal, and neuropsychiatric manifestations [54] . Age over 65, chronic lung illness, cardiovascular disease, hypertension, diabetes, and obesity are all risk factors for complications related to SARS-CoV-2 infection [55] . In the present analysis, 17 individuals had at least one comorbidity and 27 patients had no prior medical history. The average age of the patients was 48.27 years. COVID-19 neurologic symptoms range from anosmia, ageusia, encephalopathy, encephalitis, myelitis, and post-infectious sequelae such as GBS, plexopathies, and cranial neuropathies [56] . In a prospective cohort study, Rass et al. discovered neurological disorders unknown before COVID-19 in every sixth patient at the 3-month follow-up, with a predominance in ICU patients, including polyneuro/myopathy, mild encephalopathy, parkinsonism, orthostatic hypotension associated with vasovagal syncope, and stroke [57] . Similarly, Taquet et al. showed that neurological disorders are substantially more prevalent among hospitalized COVID-19 patients, particularly those admitted to the ICU [58] . According to Rass et al, seriously affected individuals had a greater prevalence of persisting neurological symptoms 3 months after disease onset than patients with milder disease courses [57] . This analysis includes the following postinfectious neurological complications: GBS, Transverse myelitis, stroke, critical illness neuromyopathy (CIN), encephalopathy, optic neuritis, myopathy, Bell's palsy, status epilepticus, vestibular neuritis, Opsoclonus Myoclonus Syndrome (OMS), and parkinsonism. Only 24 of them were hospitalized. The frequency of GBS has grown since the pandemic's breakout. There have been several publications describing the relationship between SARS-CoV-2 infection and GBS [16] . The incubation period of SARS-CoV-2 is variable, making it difficult to predict the interval between infection and the emergence of GBS [11] . Whittaker et al conducted a comprehensive evaluation of 2504 COVID-19 patients, of them, 11 cases of GBS were reported. Despite their lower proportion, these individuals suffer long-term chronic neurological impairments or even fatal consequences [12] . In this regard, there is a growing interest in the relationship between COVID-19 and the development of GBS, which nearly always occurs during the acute phase of the infection [59] . In a systematic review of 73 cases, Abu Rumeileh et al. observed that classic GBS was the most common variant identified, with sensory presentation and acute inflammatory demyelinating polyneuropathy. Rarely, variants such as Miller-Fischer syndrome or BFP have been described [60] . Several pathways have been postulated to explain the etiology of GBS after COVID-19. The most widely accepted mechanism is the development of antibodies against pathogen surface glycoproteins, which may cause peripheral nerve injury owing to similar native protein structures [16] . The vast majority of GBS with COVID 19 cases have been para infectious while post-infectious GBS is uncommon [14] . The total number of GBS cases reported after recovering from COVID-19 was 12, with a mean age of 51.4. Ten of them were males. In four of the cases, at least one comorbid condition was present. Six of them were admitted to the hospital during an active infection without being admitted to the ICU. In addition to GBS, post-infectious transverse myelitis has been reported. The pathogenesis of postinfectious myelitis is most likely similar to that of other postinfectious acute disseminated encephalomyelitis (ADEM). It involves both adaptive and innate immunity [18] . Three cases of transverse myelitis were described in the study, with a mean age of 36 years. Two of them were female. Two patients were hospitalized during an active infection but were not admitted to the ICU. In terms of enhancing recovery and selecting a better prognosis, individuals with GBS and myelitis related to COVID-19, as with other acute neurological disorders, may benefit from a neurorehabilitation intervention initiated in the early stages following the onset of neurological symptoms [61] . In a study of severe COVID-19 patients admitted to the hospital due to severe infection, encephalopathy and frontal symptoms were quite common [62] . Another study found encephalopathy in one-third of ICU patients during acute illness phases, with just one of those patients having residual symptoms three months later. At follow-up, 15% of the patients had positive frontal release signs, which are unspecific but prevalent in individuals with encephalopathy [57] . In the current meta-analysis, three cases of encephalopathy with a mean age of 68 years were described. It was not mentioned whether they were admitted to the ICU or not. Consistent with earlier studies, the risk of cerebrovascular events increased following COVID-19, with the incidence of ischemic stroke increasing to nearly one in ten (or three in 100 for a first stroke) in individuals with encephalopathy [58] . Recent studies have found that the incidence of stroke in people infected with COVID-19 varies between 0.9 and 2.7 percent [63] . SARS-CoV-2 can induce stroke by a variety of mechanisms, including invasion of the vascular endothelium, which causes coagulopathy owing to endothelial inflammation, cardiac injury, which causes clot formation, or instability of a preexisting atheroma plaque [64] . Although stroke has been reported in several studies in the context of active COVID-19, stroke after COVID-19 with no active infection has only been reported in a few case reports in the literature [21] . In this analysis, there were nine cases of post-infectious stroke, with a mean age of 56.5 years. Five of the patients were male, and five of them were admitted to the hospital during active infection without ICU hospitalization. Electrolyte and metabolic abnormalities, hypoxia, and inflammatory processes all lead to the development of seizures or abnormal electroencephalogram (EEG) patterns in individuals with severe COVID-19 [65] . Panda et al. reported 12 cases of seizure secondary to COVID-19 out of 3707 cases [66] . Seizures are becoming more common in COVID-19 patients worldwide, indicating a viral invasion of the central nervous system. Seizures are a symptom of acute brain damage induced by hypoxemia as a result of severe pneumonia. Metabolic abnormalities and septic encephalopathy are also prominent in this group of individuals. Those who have a history of status epilepticus have a worse prognosis since the severity and frequency of seizures may increase due to a lower threshold [52] . In the current study, three cases of post-infectious status epilepticus were described, one of which had a history of ICU hospitalization during the active J o u r n a l P r e -p r o o f illness. Several studies have recently revealed COVID-19-associated OMS. Interestingly, the majority of these COVID-19 patients who developed OMS had mild-to-moderate respiratory symptoms [48] . Emamikhah et al. reported seven COVID-19 patients with OMS who had normal brain MRI scans [48] . OMS post-COVID-19 was reported in only 1 case with no history of hospital admission. COVID-19 neuro-ophthalmology problems have been documented rarely [30] . Several neuroophthalmological consequences of COVID-19 have been described, either as separate events or as part of a larger neurological disorder [33] . COVID-19-related neuro-ophthalmic symptoms include optic neuritis, cranial nerve palsies, vision disturbances, and visual field abnormalities [32] . In the current meta-analysis, three cases of post-infectious optic neuritis were described. Three of them were male. Two of the patients had pre-existing medical conditions. None of them were admitted to the intensive care unit. It is also a possibility that the virus acts as an initiating agent of some neurodegenerative diseases like Parkinson's disease in the long term [6] . Although the incidence was low, concerns have been raised about post-COVID-19 parkinsonian syndromes. It might be a delayed outcome [58] . In the current analysis, one case of post-COVID-19 parkinsonism was mentioned. In conclusion, this study showed that despite recovery from acute infection, the pandemic highlights the significance of ongoing, comprehensive follow-up of all COVID-19 patients, even those initially believed to be asymptomatic, with routine screening for possible long-term persistent neurological involvement. Iraq 3. Smart Health Tower, Madam Mitterrand Street Shar hospital A novel coronavirus from patients with pneumonia in China Post covid-19 invasive pulmonary Aspergillosis: A case report Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis A systematic review of neurological symptoms and complications of COVID-19 Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series Long-Term Neurological Impact of COVID-19 Neurobiology of COVID-19 Post COVID-19 transverse myelitis; a case report with review of literature The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom Post-COVID-19 guillain-barre syndrome: A distinct neurological entity Post COVID-19 Guillain Barre Syndrome in Immunocompromised Children-A report of two cases and review of literature Post Covid Guillian-Barre Syndrome Post Covid-19 guillain barre syndrome Guillan barre syndrome in post Covid-19 infection in children Treatment related fluctuation and response to intravenous immunoglobulin therapy in post COVID-19 Guillain-Barre syndrome Guillain-barre syndrome after Covid-19 infection Evidence of Post-COVID-19 Transverse Myelitis Demyelination Acute transverse myelitis after COVID-19 pneumonia Critical illness myopathy after COVID-19 Post COVID-19 cerebral venous sinus thrombosis; a case report COVID-19 infection, depression, and ischemic stroke Alexia without agraphia in a post COVID-19 patient with left-hemisphere ischemic stroke Spontaneous thrombosis of cerebral arteriovenous malformation post COVID-19 A Case of Acute Coronary Syndrome and Ischemic Stroke After Symptomatic Resolution of COVID-19 Long-segment arterial cerebral vessel thrombosis after mild COVID-19 A 14-Year-Old Male Patient with Kawasaki Disease Presented with Stroke after COVID-19 New-onset refractory status epilepticus (NORSE) in post SARS-CoV-2 autoimmune encephalitis: a case report Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case Quadrantanopia as the only symptom of post-COVID stroke in the occipital pole: Case report Post COVID-19 optic neuritis: Two Egyptian case reports Antiaquaporin 4-Related Optic Neuritis and Myelitis Post-COVID-19 Infection Post COVID-19 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis Optic neuritis in post-Covid rhinoorbito-cerebral mucormycosis (ROCM): A rare presentation Optic neuritis as a presenting symptom of post-COVID-19 multisystem inflammatory syndrome in children (MIS-C) Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period Post-COVID-19 inflammatory syndrome manifesting as refractory status epilepticus Post-COVID Syndrome (MIS-C) with Refractory Status Epilepticus Report of a Child with Febrile Status Epilepticus and Post-COVID Multi-System Inflammatory Syndrome Bickerstaff encephalitis after COVID-19 Post-infectious focal encephalitis due to COVID-19 Successful management of post-COVID-19 acanthamoebic encephalitis Post-infectious SARS-CoV-2 autoimmune encephalitis associated with N-type calcium channel antibodies Bell's palsy following post COVID-19 infection myocarditis in pregnancy: The first case report A case of post COVID-19 multisystem inflammatory syndrome and Bell's palsy in a young adult Post COVID-19 Bilateral Facial Nerve Palsy: A Case Report A unique association of bifacial weakness, paresthesia and vestibulocochlear neuritis as post-COVID-19 manifestation in pregnant women: a case report Post-COVID Opsoclonus Myoclonus Syndrome: A Case Report From Pakistan The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection Post COVID-19 pulmonary complications; a single center experience. Annals of Medicine and Surgery COVID-19: review of a 21st century pandemic from etiology to neuro-psychiatric implications Post-COVID 19 neurological syndrome: implications for sequelae's treatment Post COVID-19 longitudinally extensive transverse myelitis (LETM)-a case report Post COVID-19 neurological syndrome: A prospective study at 3600 m above sea level in La Paz Bolivia Post-acute COVID-19 neurological syndrome: A new medical challenge Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry Guillain-Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases Clinical and Electrophysiological Outcome Measures of Patients With Post-Infectious Neurological Syndromes Related to COVID-19 Treated With Intensive Neurorehabilitation Neurologic features in severe SARS-CoV-2 infection COVID-19: patients with stroke or risk of stroke COVID-19 and cerebrovascular diseases: a systematic review and perspectives for stroke management Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic Neurological complications of SARS-CoV-2 infection in children: a systematic review and meta-analysis J o u r n a l P r e -p r o o f • SARS-CoV-2 is most commonly associated with pneumonia.• However, new studies have indicated that many other organ systems can be involved.• Also various neurological sequelae in COVID-19 individuals have been identified.• The specific relationship between the infection and neurological disorders remains unknown.• In this study, metadata were discussed regarding post COVID-19 neurological complications J o u r n a l P r e -p r o o f The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated. All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.There is no conflict to be declared. All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.No source to be stated Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informedThe manuscript approved by ethical committee of the University of Sulaimani J o u r n a l P r e -p r o o f consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Consent has been taken from the patients and the family of the patients Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. It is not applicable for meta-analysis The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish